About Us
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
|
|
Previous Close | $135.27 | Open | $134.45 |
Volume | 1.57M | Market Cap | 13.372B |
Yield | Last Dividend |
Liquid Biopsy Market On Target to Reach ... | 03/03/21 |
Rise in demand for non-invasive, safe procedures, increase in prevalence of cancer, and benefits over traditional test procedures would drive the grow... |
Guardant360?? CDx Liquid Biopsy CE-Marke... | 03/02/21 |
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH) has CE-marked Guardant360?? CDx for tumor mutation profiling, also known as ... |
Guardant Health Reports Fourth Quarter a... | 02/24/21 |
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company focused on helping conquer cancer glob... |
Guardant Health to Participate in Upcomi... | 02/17/21 |
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will be p... |
Guardant Health Launches Guardant Reveal... | 02/16/21 |
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced the availability of Guardan... |
The Daily Biotech Pulse: European Regula... | 02/12/21 |
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 12) 4D ... |
Guardant Health : to Report Fourth Quart... | 02/04/21 |
Guardant Health, Inc. , a leading precision oncology company, today announced it will report financial results for the fourth quarter and full year 20... |
Guardant Health to Report Fourth Quarter... | 02/04/21 |
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financ... |
Head-to-Head Study Shows Guardant360 Liq... | 01/27/21 |
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH). Despite guideline recommendations for comprehensive genomic profiling (CGP)... |
Guardant Health : and Vall d'Hebron Inst... | 01/18/21 |
Guardant Health, Inc. , a leading precision oncology company, and Vall d???Hebron Institute of Oncology , one of Europe???s leading cancer research or... |
Guardant Health and Vall d???Hebron Inst... | 01/18/21 |
BARCELONA, Spain & REDWOOD CITY, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, and Vall d???Hebro... |
The Daily Biotech Pulse: Bausch Health I... | 01/13/21 |
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Jan. 12) Abb... |
The Daily Biotech Pulse: GSK, Vir To Sta... | 01/12/21 |
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Jan. 11) 10X... |
GUARDANT HEALTH, INC. : Entry into a Mat... | 01/07/21 |
Item 1.01. Entry into a Material Definitive Agreement. On January 1, 2021, Guardant Health, Inc. entered into an Amendment #5 to Supply Agreement with... |
Guardant Health to Participate in the 39... | 12/30/20 |
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will be p... |
Canaccord Genuity Stick to Their Buy Rat... | 12/25/20 |
Canaccord Genuity Stick to Their Buy Rating for Guardant Health |
Liquid Biopsy Market 2020 Global Key Cou... | 12/15/20 |
Market Insights: Liquid biopsy overcomes these problems of tissue biopsy by using biomarkers present in samples such as blood, urine etc. and thus is ... |
Guardant Health Names Michael Bell as Ne... | 12/11/20 |
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, has named Michael Bell as the company... |
The Daily Biotech Pulse: Pfizer-BioNTech... | 12/02/20 |
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Dec. 1) AbbV... |
Guardant Health, Inc. Announces Proposed... | 11/16/20 |
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH) today announced its intention to offer, subject to market and other conditio... |
The Daily Biotech Pulse: Urovant In M&A ... | 11/13/20 |
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Nov. 12) ALX... |
Canaccord Genuity Stick to Their Buy Rat... | 11/06/20 |
Canaccord Genuity Stick to Their Buy Rating for Guardant Health |
Guardant Health Reports Third Quarter 20... | 11/05/20 |
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company focused on helping conquer cancer glob... |
The Daily Biotech Pulse: Bluebird Bio Pl... | 11/05/20 |
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Nov. 4) Abbo... |
Global $12.9 Billion Liquid Biopsy Marke... | 10/20/20 |
DUBLIN, Oct. 20, 2020 /PRNewswire/ -- The "Global Liquid Biopsy Market: Focus on Market Segmentation by Product Type, by Indication Type, by Technolog... |
Guardant Health Announces Webcast of Thi... | 10/16/20 |
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH) today announced it will report financial results for the third quarter 2020 ... |
Guardant Health Announces Closing of Pub... | 10/15/20 |
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH) (???Guardant Health???), a leading precision oncology company focused on hel... |
Guardant Health Announces Pricing of Pub... | 10/07/20 |
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH) (???Guardant Health???), a leading precision oncology company focused on hel... |
Guardant Health readies common stock PPO... | 10/06/20 |
Guardant Health (NASDAQ:GH) +1.1% PM, commenced a proposed underwritten public offering of 7M shares of its common stock being offered for sale by Sof... |
The Daily Biotech Pulse: Eton Snags Seco... | 09/30/20 |
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 29) Ac... |
Strong Buy rating | 02/26/21 |
Morgan Stanley maintains Overweight rating and raises Price Target from $130.00 to $175.00 |
Buy rating | 02/25/21 |
Citigroup maintains Buy rating and raises Price Target from $155.00 to $190.00 |
Strong Buy rating | 02/25/21 |
Cowen & Co. maintains Outperform rating and raises Price Target from $140.00 to $190.00 |
Strong Buy rating | 01/20/21 |
SVB Leerink maintains Outperform rating and raises Price Target from $150.00 to $190.00 |
Buy rating | 01/11/21 |
Stifel initiates coverage with Buy rating and announces Price Target of $175.00 |
Strong Buy rating | 12/11/20 |
SVB Leerink maintains Outperform rating and raises Price Target from $130.00 to $150.00 |
Date | 2021-02-24 (AMC) | Est. (EPS/Rev.) | ($0.57)/ 76.73M |
Actual (EPS/Rev.) | $-0.94/ $78.32 M | EPS (TTM) | 0 |
Total Revenue | $1.3B | Total Liabilities | $2.1B |
Cost of Revenue | $2.5B | Total cash flow | $3.2 |
Total Assets | $29.98B |
% Insider | 12.52% | % Institutional | 76.43% |
Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
Service Name | Trader | % Success | |
---|---|---|---|
High Growth Stocks- Long only | Srini Donapati | 70.00 % | Follow |
Alpha Swing Trades | Jonathan | 68.00 % | Follow |
Optioneering-W | Sam Allen | 27.00 % | Follow |
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
We are not a registered investment advisor. All investments involve risk, individual's trading does not guarantee future results or returns. Investors are fully responsible for any investment decisions they make. References to specific securities should not be construed as a recommendation to buy or sell that security only mentioned for informational purposes.